TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38740027

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (lopinavir 400 mg twice daily + ritonavir 100 mg twice daily)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Raltegravir (raltegravir 400 mg twice daily)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Triple nucleoside reverse transcriptase inhibitor (NRTI) group (tenofovir 245 mg once daily + emtricitabine 200 mg once daily + zidovudine 250 mg twice daily)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Ritonavir-boosted lopinavir group
Number of subjects: 210

Group type: COMPARATOR
Intervention: Raltegravir group
Number of subjects: 210
Study: 38740030

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 132
Study: 38740044

Group type: EXPERIMENTAL
Intervention: Surgery and chemotherapy
Number of subjects: 335

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 335
Study: 38740133

Group type: EXPERIMENTAL
Intervention: Anapen (BioProject)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: EpiPen (Mylan)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Jext (ALK)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Emerade (Medeca)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Compression
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Older men
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Obesity-related variables
Number of subjects: 68
Study: 38740271

Group type: EXPERIMENTAL
Intervention: Artificial intelligence age estimation from transthoracic echocardiography
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Artificial intelligence sex prediction from transthoracic echocardiography
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Age prediction ≥5 years vs chronologic age
Number of subjects: 319
Study: 38740297

Group type: EXPERIMENTAL
Intervention: Home health aides intervention
Number of subjects: 6000000
Study: 38740298

Group type: EXPERIMENTAL
Intervention: Structured approach and checklist for assessing site readiness to contribute EHR data
Number of subjects: 5451

Group type: EXPERIMENTAL
Intervention: Assessment of infrastructure, data procurement, and cost of obtaining study data
Number of subjects: 5451

Group type: EXPERIMENTAL
Intervention: Rigorous, prospective vetting of data quality and infrastructure
Number of subjects: 5451
Study: 38740493

Group type: EXPERIMENTAL
Intervention: Erdafitinib alone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Erdafitinib with carbamazepine
Number of subjects: 13
Study: 38740496

Group type: EXPERIMENTAL
Intervention: Adolescents living with obesity (ALwO)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Caregivers of ALwO
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Healthcare professionals (HCPs)
Number of subjects: 1200
Study: 38740499

Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (LDN) starting at 1 mg daily, up-titrated to 4.5 mg daily or maximum tolerated dose over 16 weeks.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo starting at 1 mg daily, up-titrated to 4.5 mg daily or maximum tolerated dose over 16 weeks.
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (LDN)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 38740532

Group type: EXPERIMENTAL
Intervention: High-intensity care (HIC) consisting of rapid up-titration of guideline-directed medical therapy (GDMT) and close follow-up
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: High-intensity care (HIC)
Number of subjects: 1078
Study: 38740618

Group type: EXPERIMENTAL
Intervention: e-APA (adapted physical activity program)
Number of subjects: 35

Group type: COMPARATOR
Intervention: e-HE (health education program)
Number of subjects: 35
Study: 38740702

Group type: EXPERIMENTAL
Intervention: AYA cancer survivors
Number of subjects: 3776

Group type: EXPERIMENTAL
Intervention: Health-related conditions reported
Number of subjects: 3776

Group type: EXPERIMENTAL
Intervention: Factors associated with health-related conditions
Number of subjects: 3776
Study: 38740817

Group type: EXPERIMENTAL
Intervention: Atherogenic index of plasma (AIP) increase (per-0.1 unit) in non-AMI patients
Number of subjects: 10735

Group type: EXPERIMENTAL
Intervention: High platelet reactivity (HPR)
Number of subjects: 10735

Group type: EXPERIMENTAL
Intervention: Atherogenic index of plasma (AIP) levels
Number of subjects: 10735
Study: 38740901

Group type: EXPERIMENTAL
Intervention: High-ELS group
Number of subjects: 163

Group type: COMPARATOR
Intervention: No-ELS and moderate-ELS groups
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 163
Study: 38740993

Group type: EXPERIMENTAL
Intervention: semaglutide
Number of subjects: 17604

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17604
Study: 38740994

Group type: EXPERIMENTAL
Intervention: Emotional distress (ED) present
Number of subjects: 227

Group type: COMPARATOR
Intervention: Emotional distress (ED) absent
Number of subjects: 227
Study: 38741101

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 255
Study: 38741174

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified balanced energy and protein (BEP) supplementation
Number of subjects: 240

Group type: COMPARATOR
Intervention: Multiple micronutrient supplements (MMS)
Number of subjects: 240
Study: 38741218

Group type: EXPERIMENTAL
Intervention: Surgical left atrial appendage (LAA) closure during open-heart surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38741375

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Retreatment with immune checkpoint inhibitors (ICIs)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Retreatment with ICIs
Number of subjects: 45
Study: 38741385

Group type: EXPERIMENTAL
Intervention: In-person intervention
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Remote intervention
Number of subjects: 415
Study: 38741607

Group type: EXPERIMENTAL
Intervention: rhPTH(1-84) 50 μg once daily, adjusted based on albumin-corrected serum calcium levels
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: rhPTH(1-84) 50 μg once daily
Number of subjects: 22
Study: 38741776

Group type: EXPERIMENTAL
Intervention: Joint cancer screening
Number of subjects: 5506

Group type: EXPERIMENTAL
Intervention: Joint cancer screening with good compliance
Number of subjects: 5506

Group type: EXPERIMENTAL
Intervention: Joint cancer screening with poor compliance
Number of subjects: 5506

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5506
Study: 38741917

Group type: EXPERIMENTAL
Intervention: Economic support (3 USD/month for girls, 35 USD/year for guardians, up to 150 USD/year for school fees)
Number of subjects: 4110

Group type: EXPERIMENTAL
Intervention: Economic support plus community dialogue
Number of subjects: 4110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4110

Group type: EXPERIMENTAL
Intervention: Economic support
Number of subjects: 4110
Study: 38742219

Group type: EXPERIMENTAL
Intervention: Volume control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pressure control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive pressure control
Number of subjects: 0
Study: 38742248

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38742491

Group type: EXPERIMENTAL
Intervention: Manual FFR pullbacks used to calculate PPG; primary outcome of optimal revascularization defined as an FFR ≥0.88 after PCI.
Number of subjects: 993
Study: 38742509

Group type: EXPERIMENTAL
Intervention: Computed Tomography Angiography (CTA)
Number of subjects: 145
Study: 38742522

Group type: EXPERIMENTAL
Intervention: Coronary embolism (CE) in patients with STEMI and AF (group A)
Number of subjects: 2292

Group type: COMPARATOR
Intervention: Atherosclerotic cause in patients with STEMI and AF (group B)
Number of subjects: 2292

Group type: COMPARATOR
Intervention: Patients without AF and CE (group C)
Number of subjects: 2292
Study: 38742554

Group type: EXPERIMENTAL
Intervention: Veil sparing HoLEP (VS-HoLEP)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard HoLEP (St-HoLEP)
Number of subjects: 180
Study: 38742577

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided access
Number of subjects: 544

Group type: COMPARATOR
Intervention: Fluoroscopy-guided access
Number of subjects: 544
Study: 38742581

Group type: EXPERIMENTAL
Intervention: Biolimus-coated balloon (BCB)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Paclitaxel-coated balloon (PCB)
Number of subjects: 280
Study: 38742842

Group type: EXPERIMENTAL
Intervention: CSCT
Number of subjects: 129

Group type: COMPARATOR
Intervention: VUIMT
Number of subjects: 129

Group type: COMPARATOR
Intervention: Open Surgery
Number of subjects: 129
Study: 38742855

Group type: EXPERIMENTAL
Intervention: Fatigued patients
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: COVID-19 survivors
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 59
Study: 38742915

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 38742940

Group type: EXPERIMENTAL
Intervention: Biofeedback-based virtual reality (VR-BF)
Number of subjects: 23
Study: 38743047

Group type: EXPERIMENTAL
Intervention: Stool from vaginally seeded infants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo) seeding
Number of subjects: 0
Study: 38743059

Group type: EXPERIMENTAL
Intervention: Plitidepsin
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (non-treated patients)
Number of subjects: 54
Study: 38743075

Group type: EXPERIMENTAL
Intervention: Intra-operative injection of bupivacaine into the obturator membrane
Number of subjects: 22

Group type: COMPARATOR
Intervention: No injection (control)
Number of subjects: 22
Study: 38743040

Group type: EXPERIMENTAL
Intervention: Pancreatic surgery in low-to-middle-HDI countries
Number of subjects: 4223

Group type: EXPERIMENTAL
Intervention: Pancreatic surgery in high-HDI countries
Number of subjects: 4223

Group type: EXPERIMENTAL
Intervention: Pancreatic surgery in very high-HDI countries
Number of subjects: 4223

Group type: EXPERIMENTAL
Intervention: Overall pancreatic surgery outcomes
Number of subjects: 4223

Group type: EXPERIMENTAL
Intervention: Failure-to-rescue rate in low-to-middle-HDI countries
Number of subjects: 4223

Group type: EXPERIMENTAL
Intervention: Failure-to-rescue rate in very high-HDI countries
Number of subjects: 4223

Group type: EXPERIMENTAL
Intervention: Complications of any severity
Number of subjects: 4223

Group type: EXPERIMENTAL
Intervention: Major complications (Clavien-Dindo grade at least IIIa)
Number of subjects: 4223
Study: 38743155

Group type: EXPERIMENTAL
Intervention: Dupilumab (200 mg for body weight ≥ 5 kg to < 15 kg; 300 mg for body weight ≥ 15 kg to < 30 kg) every 4 weeks for 1 year
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 142
Study: 38743248

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment for periodontitis
Number of subjects: 45

Group type: COMPARATOR
Intervention: Periodontitis
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 45

Group type: COMPARATOR
Intervention: Gingivitis
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ROC analysis for Galectin-1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ROC analysis for Galectin-3
Number of subjects: 45
Study: 38743265

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - 8 weekly sessions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Whole-Body Hyperthermia (WBH) - 8 weekly sessions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) and Whole-Body Hyperthermia (WBH) combined
Number of subjects: 16
Study: 38743288

Group type: EXPERIMENTAL
Intervention: Monthly high-dose vitamin D supplementation
Number of subjects: 0
Study: 38743388

Group type: EXPERIMENTAL
Intervention: EthioPerm (Permanent ostomy patients in Ethiopia)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: EthioTemp (Temporary ostomy patients in Ethiopia)
Number of subjects: 66

Group type: COMPARATOR
Intervention: SweSto (Ostomy patients in Sweden)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: EthioPerm
Number of subjects: 66

Group type: COMPARATOR
Intervention: SweSto
Number of subjects: 66
Study: 38743423

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (CTD)
Number of subjects: 13523

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 13523
Study: 38743473

Group type: EXPERIMENTAL
Intervention: Transdiagnostic CBT
Number of subjects: 150

Group type: COMPARATOR
Intervention: WAIT (Waitlist)
Number of subjects: 150
Study: 38743564

Group type: EXPERIMENTAL
Intervention: Pulsed-xenon UV (PX-UV) disinfection after standard terminal cleaning
Number of subjects: 25732

Group type: COMPARATOR
Intervention: Sham disinfection (control)
Number of subjects: 25732
Study: 38743692

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated vaccine (TIV)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Pre-existing ADCP scores ≥250
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: ADCD scores of ≥25
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: ADCD scores of ≥15
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study: 38743716

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Prison treatment as usual (Control)
Number of subjects: 460
Study: 38743727

Group type: EXPERIMENTAL
Intervention: After-discharge complete revascularization (CR)
Number of subjects: 258

Group type: COMPARATOR
Intervention: In-hospital complete revascularization (CR)
Number of subjects: 258
Study: 38743939

Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality intervention for preoperative anxiety (PSA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: VR control (nature trek)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual group
Number of subjects: 0
Study: 38743958

Group type: EXPERIMENTAL
Intervention: Gestational age-based dosing of UFH (5,000 units subcutaneously every 12 hours in first trimester; 7,500 units in second trimester; 10,000 units in third trimester)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard dosing of UFH (5,000 units subcutaneously every 12 hours)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Gestational age-based dosing of UFH
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard dosing of UFH
Number of subjects: 46
Study: 38744144

Group type: EXPERIMENTAL
Intervention: Quizartinib (30 mg, 40 mg, or 60 mg) in combination with azacitidine
Number of subjects: 12
Study: 38744428

Group type: EXPERIMENTAL
Intervention: Wireless Feedback System (WFS)
Number of subjects: 400

Group type: COMPARATOR
Intervention: WFS plus coaching
Number of subjects: 400

Group type: COMPARATOR
Intervention: WFS vs WFS plus coaching
Number of subjects: 400

Group type: COMPARATOR
Intervention: Modest vs vigorous step-up interventions among nonresponders
Number of subjects: 400
Study: 38744460

Group type: EXPERIMENTAL
Intervention: First Disease-Modifying Therapy (DMT)
Number of subjects: 1587

Group type: EXPERIMENTAL
Intervention: DMT Switch
Number of subjects: 1587

Group type: EXPERIMENTAL
Intervention: First DMT
Number of subjects: 1587
Study: 38744598

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S booster in Arm A1 (n = 361)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S booster in hybrid-immunity subgroup (Arm A1)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S booster in Arm A2 (n = 104)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S booster in ≥ 60-year-olds
Number of subjects: 465
Study: 38744750

Group type: EXPERIMENTAL
Intervention: Intervention group (I)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Comparison group (C)
Number of subjects: 205
Study: 38744792

Group type: EXPERIMENTAL
Intervention: Phase-locked acoustic stimulation (PLAS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study: 38744804

Group type: EXPERIMENTAL
Intervention: Sleepiz One + device
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Sleepiz One +  device with additional SpO2 information
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Sleepiz One +  device without additional SpO2 information
Number of subjects: 141

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 141
Study: 38744844

Group type: EXPERIMENTAL
Intervention: ARCT-154 vaccine (two doses, 28 days apart)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ARCT-154 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study: 38744929

Group type: EXPERIMENTAL
Intervention: restricted diet including calorie restriction, hot water drinking, walking, and sexual self-restraint
Number of subjects: 70
Study: 38745011

Group type: EXPERIMENTAL
Intervention: PR006 gene therapy
Number of subjects: 13
Study: 38745158

Group type: EXPERIMENTAL
Intervention: Concentrated transdiagnostic and micro choice-based group treatment
Number of subjects: 67
Study: 38745175

Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 55
Study: 38745176

Group type: EXPERIMENTAL
Intervention: Dance intervention program (1 hour of online dance classes per week for 10 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (10-week waiting period)
Number of subjects: 43
Study: 38745227

Group type: EXPERIMENTAL
Intervention: Task-oriented training assisted by a force feedback rehabilitation robot for 20 min/day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional task-oriented training assisted by therapists for 20 min/day
Number of subjects: 44
Study: 38745260

Group type: EXPERIMENTAL
Intervention: GGED-AD app used for 14 consecutive days for approximately 5 minutes each day.
Number of subjects: 0

Group type: COMPARATOR
Intervention: GGNEUTRAL app used for 14 consecutive days for approximately 5 minutes each day.
Number of subjects: 0
Study: 38745306

Group type: EXPERIMENTAL
Intervention: Single Bond Universal by 3 M ESPE
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Xeno-V+ by Dentsply
Number of subjects: 105

Group type: COMPARATOR
Intervention: Bifluorid 12 by Voco (Control)
Number of subjects: 105
Study: 38745312

Group type: EXPERIMENTAL
Intervention: Personal agency-based training for women (2 days) and their male partners (1 day)
Number of subjects: 1061
Study: 38745322

Group type: EXPERIMENTAL
Intervention: Video Therapy (VT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Mirror Therapy (MT)
Number of subjects: 33
Study: 38745333

Group type: EXPERIMENTAL
Intervention: Preoperative hypofractionated proton beam therapy (PBT) - 30 Gy radiobiological equivalent in 5 fractions delivered every other day.
Number of subjects: 40
Study: 38745502

Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 2859

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 2859
Study: 38745592

Group type: EXPERIMENTAL
Intervention: EHR-based weight management intervention delivered through the patient portal with primary care staff as coaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation tracking metrics for IT tools
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive multi-level implementation approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive involvement of clinic leadership
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Socio-technical formative evaluation methods
Number of subjects: 0
Study: 38745965

Group type: EXPERIMENTAL
Intervention: TACE-ICI-VEGF
Number of subjects: 1244
Study: 38745967

Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 38745983

Group type: EXPERIMENTAL
Intervention: Intravenous administration of indocyanine green (ICG) fluorescence imaging
Number of subjects: 14

Group type: COMPARATOR
Intervention: Fluorescence parameters and clinical variables
Number of subjects: 14
Study: 38745998

Group type: EXPERIMENTAL
Intervention: Cash incentives (up to SGD50 per month)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hedonic incentives (up to SGD50 per month)
Number of subjects: 0
Study: 38746060

Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA Lot 1
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA Lot 2
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA Lot 3
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: Solicited AEs
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: Unsolicited AEs
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: Serious AEs (SAEs)
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: SAEs with fatal outcome
Number of subjects: 757
Study: 38746125

Group type: EXPERIMENTAL
Intervention: Multimodal, digitally enhanced intervention including a smartwatch, study app, mobile integrated health program, and virtual pulmonary support service.
Number of subjects: 100
Study: 38746205

Group type: EXPERIMENTAL
Intervention: TELESCOPE intervention: telehealth decision coaching session about LCS delivered by trained patient navigators, with a low-dose CT scan (LDCT) order placed for each patient wanting LCS.
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: TELESCOPE intervention: telehealth decision coaching booster session with a navigator for patients whose initial LCS showed low-risk findings.
Number of subjects: 420

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC): patients receive enhanced usual care from a clinician, with access to a Continuing Medical Education (CME) webinar about LCS and an LCS discussion guide.
Number of subjects: 420
Study: 38746210

Group type: EXPERIMENTAL
Intervention: Detectable total testosterone levels in females
Number of subjects: 215

Group type: COMPARATOR
Intervention: Undetectable total testosterone levels in females
Number of subjects: 215
Study: 38746215

Group type: EXPERIMENTAL
Intervention: Ketone ester (bis-octanoyl (R)-1,3-butanediol)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PLA) containing canola oil
Number of subjects: 30
Study: 38746220

Group type: EXPERIMENTAL
Intervention: Ribociclib 800mg daily plus Gemcitabine 1000mg/m2
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ribociclib plus Gemcitabine
Number of subjects: 43